Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation

Background: Poly ADP-ribose polymerase inhibitors (PARPis) are widely used for patients with BRCA1/2 mutations. However, until now, there is no available evidence reported for the efficiency of PARPis in cutaneous squamous cell carcinoma (cSCC). Case presentation: We presented a case of a 40-year-ol...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xin, Chen, Wenjuan, Qu, Xiujuan, Chen, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411933/
https://www.ncbi.nlm.nih.gov/pubmed/36034850
http://dx.doi.org/10.3389/fphar.2022.968060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411933/
https://www.ncbi.nlm.nih.gov/pubmed/36034850
http://dx.doi.org/10.3389/fphar.2022.968060

Ejemplares similares